Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.

Spec A, Pullman J, Thompson GR, Powderly WG, Tobin EH, Vazquez J, Wring SA, Angulo D, Helou S, Pappas PG; Mycoses Study Group .

J Antimicrob Chemother. 2019 Oct 1;74(10):3056-3062. doi: 10.1093/jac/dkz277.

PMID:
31304536
2.

Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Van Bocxlaer K, Gaukel E, Hauser D, Park SH, Schock S, Yardley V, Randolph R, Plattner JJ, Merchant T, Croft SL, Jacobs RT, Wring SA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02419-17. doi: 10.1128/AAC.02419-17. Print 2018 May.

3.

Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase.

Volkov OA, Brockway AJ, Wring SA, Peel M, Chen Z, Phillips MA, De Brabander JK.

J Med Chem. 2018 Feb 8;61(3):1182-1203. doi: 10.1021/acs.jmedchem.7b01654. Epub 2018 Jan 5.

4.

Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.

Thompson AM, Marshall AJ, Maes L, Yarlett N, Bacchi CJ, Gaukel E, Wring SA, Launay D, Braillard S, Chatelain E, Mowbray CE, Denny WA.

Bioorg Med Chem Lett. 2018 Jan 15;28(2):207-213. doi: 10.1016/j.bmcl.2017.10.067. Epub 2017 Oct 27.

5.

Synthesis and evaluation of analogs of 5'-(((Z)-4-amino-2-butenyl)methylamino)-5'-deoxyadenosine (MDL 73811, or AbeAdo) - An inhibitor of S-adenosylmethionine decarboxylase with antitrypanosomal activity.

Brockway AJ, Volkov OA, Cosner CC, MacMillan KS, Wring SA, Richardson TE, Peel M, Phillips MA, De Brabander JK.

Bioorg Med Chem. 2017 Oct 15;25(20):5433-5440. doi: 10.1016/j.bmc.2017.07.063. Epub 2017 Aug 3.

6.

Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.

Volkov OA, Cosner CC, Brockway AJ, Kramer M, Booker M, Zhong S, Ketcherside A, Wei S, Longgood J, McCoy M, Richardson TE, Wring SA, Peel M, Klinger JD, Posner BA, De Brabander JK, Phillips MA.

ACS Infect Dis. 2017 Jul 14;3(7):512-526. doi: 10.1021/acsinfecdis.7b00022. Epub 2017 Apr 7.

7.

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

Wring SA, Randolph R, Park S, Abruzzo G, Chen Q, Flattery A, Garrett G, Peel M, Outcalt R, Powell K, Trucksis M, Angulo D, Borroto-Esoda K.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02068-16. doi: 10.1128/AAC.02068-16. Print 2017 Apr.

8.

Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis.

Jacobs RT, Plattner JJ, Nare B, Wring SA, Chen D, Freund Y, Gaukel EG, Orr MD, Perales JB, Jenks M, Noe RA, Sligar JM, Zhang YK, Bacchi CJ, Yarlett N, Don R.

Future Med Chem. 2011 Aug;3(10):1259-78. doi: 10.4155/fmc.11.80.

PMID:
21859301
9.

SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis.

Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, Jenks MX, Noe RA, Bowling TS, Mercer LT, Rewerts C, Gaukel E, Owens J, Parham R, Randolph R, Beaudet B, Bacchi CJ, Yarlett N, Plattner JJ, Freund Y, Ding C, Akama T, Zhang YK, Brun R, Kaiser M, Scandale I, Don R.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1151. doi: 10.1371/journal.pntd.0001151. Epub 2011 Jun 28.

10.

SAR of 2-amino and 2,4-diamino pyrimidines with in vivo efficacy against Trypanosoma brucei.

Perales JB, Freeman J, Bacchi CJ, Bowling T, Don R, Gaukel E, Mercer L, Moore JA 3rd, Nare B, Nguyen TM, Noe RA, Randolph R, Rewerts C, Wring SA, Yarlett N, Jacobs RT.

Bioorg Med Chem Lett. 2011 May 15;21(10):2816-9. doi: 10.1016/j.bmcl.2011.03.097. Epub 2011 Apr 1.

PMID:
21507639
11.

Method to screen substrates of apical sodium-dependent bile acid transporter.

Rais R, Gonzalez PM, Zheng X, Wring SA, Polli JE.

AAPS J. 2008 Dec;10(4):596-605. doi: 10.1208/s12248-008-9069-9. Epub 2008 Dec 16.

12.

Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.

Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, Hoh R, Liegler T, Spudich S, Kuritzkes DR, Deeks SG.

Antivir Ther. 2008;13(3):369-74.

13.

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.

Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.

15.
16.

Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).

Harris M, Joy R, Larsen G, Valyi M, Walker E, Frick LW, Palmatier RM, Wring SA, Montaner JS.

AIDS. 2006 Mar 21;20(5):719-23.

PMID:
16514302
17.

Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.

Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkison KK, Polli JW.

Pharmacology. 2004 Oct;72(2):92-8.

PMID:
15331914
18.

Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model.

Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS.

J Pharm Sci. 2004 Apr;93(4):957-68.

PMID:
14999732
19.

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW.

J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.

PMID:
12438524
20.

Automated quantitative and qualitative analysis of metabolic stability: a process for compound selection during drug discovery.

Wring SA, Silver IS, Serabjit-Singh CJ.

Methods Enzymol. 2002;357:285-95. No abstract available.

PMID:
12424918
21.

Rational use of in vitro P-glycoprotein assays in drug discovery.

Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.

J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.

PMID:
11602674
22.

Influence of passive permeability on apparent P-glycoprotein kinetics.

Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE.

Pharm Res. 2000 Dec;17(12):1456-60.

PMID:
11303953
23.

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.

Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW.

Drug Metab Dispos. 2001 May;29(5):754-60.

PMID:
11302944
24.

Simultaneous determination of zidovudine and lamivudine in human serum using HPLC with tandem mass spectrometry.

Kenney KB, Wring SA, Carr RM, Wells GN, Dunn JA.

J Pharm Biomed Anal. 2000 Jul;22(6):967-83.

PMID:
10857566
25.

Shorter development of immunoassay for drugs: application of the novel RIMMS technique enables rapid production of monoclonal antibodies to ranitidine.

Wring SA, Kilpatrick KE, Hutchins JT, Witherspoon SM, Ellis B, Jenner WN, Serabjit-Singh C.

J Pharm Biomed Anal. 1999 Apr;19(5):695-707.

PMID:
10698534
27.

Rapid development of affinity matured monoclonal antibodies using RIMMS.

Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Caterson B, McIntyre GD.

Hybridoma. 1997 Aug;16(4):381-9.

PMID:
9309429
28.

The production and evaluation of a radioligand and antiserum for the radioimmunoassay of subnanogram per millilitre concentrations of lamivudine.

Wring SA, O'Neill RM, Williams JL, Jenner WN, Daniel MJ, Gray MR, Newman JJ, Wells GN, Sutherland DR.

J Pharm Biomed Anal. 1994 Dec;12(12):1573-83. No abstract available.

PMID:
7696382
29.

Radioimmunoassay for the determination of alosetron in human urine and saliva.

Wring SA, O'Neill RM, Williams JL, Birch HL, Goddard CP, Andrew PD, Jenner WN.

Analyst. 1994 Nov;119(11):2395-401.

PMID:
7872486
30.

A sensitive radioimmunoassay, combined with solid-phase extraction, for the sub-nanogram per ml determination of ondansetron in human plasma.

Wring SA, Rooney RM, Goddard CP, Waterhouse I, Jenner WN.

J Pharm Biomed Anal. 1994 Mar;12(3):361-71.

PMID:
8031936
33.

Supplemental Content

Loading ...
Support Center